XTL Biopharmaceuticals Ltd. (XTLB)

XTL Biopharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	May 13, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	11	22	5	6	15	16
Market Cap Growth	322.69%	322.69%	-16.65%	-57.56%	-4.50%	124.03%
Enterprise Value	10	21	3	2	12	12
Last Close Price	1.30	2.03	1.01	1.21	2.77	3.03
PE Ratio	-	-	-	-	34.41	-
PS Ratio	24.61	49.63	-	-	-	-
PB Ratio	2.04	4.12	2.38	1.59	2.81	4.34
P/TBV Ratio	-	-	2.88	1.76	3.02	4.85
EV/Sales Ratio	22.34	45.74	-	-	-	-
Debt / Equity Ratio	0.03	0.03	-	-	-	-
Asset Turnover	0.08	0.08	-	-	-	-
Quick Ratio	0.56	0.56	9.74	19.90	26.52	23.79
Current Ratio	0.61	0.61	9.93	20.35	27.00	24.10
Return on Equity (ROE)	-26.83%	-26.83%	-57.31%	-28.89%	9.73%	-58.34%
Return on Assets (ROA)	-24.74%	-24.74%	-14.46%	-10.18%	-9.82%	-8.64%
Return on Capital (ROIC)	-34.84%	-34.84%	-15.38%	-11.79%	-14.41%	-11.70%
Earnings Yield	-9.25%	-4.59%	-33.65%	-21.22%	2.91%	-18.84%
FCF Yield	-15.06%	-7.47%	-13.35%	-14.18%	-7.01%	-5.43%
Buyback Yield / Dilution	-29.23%	-29.23%	0.00%	11.48%	-19.71%	-

Updated Dec 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q